NASDAQ$AMLX
Amylyx Pharmaceuticals Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Amylyx reported financial results for the quarter ended March 31, 2022.
Amylyx Pharmaceuticals reported a net loss of $47.8 million for the first quarter of 2022. The company is focused on commercial launch readiness to support AMX0035 for ALS treatment and engaging with regulators for potential approvals.
- Regulatory applications for AMX0035 are under review in the U.S., Canada, and Europe.
- New analyses from the CENTAUR trial demonstrated a significant survival benefit of AMX0035.
- Safety and tolerability data from CENTAUR and PEGASUS trials were presented at the 2022 AAN Annual Meeting.
- An Expanded Access Program (EAP) for AMX0035 was launched in the U.S. for eligible people living with ALS.
Headline financials
Revenue & EPS history
Amylyx · Revenue · Quarterly
$0
Forward guidance
The company is focused on advancing AMX0035 through regulatory processes and preparing for potential commercial launch.
Tailwinds
- Potential regulatory approval of AMX0035 in the U.S., Canada, and Europe.
- Ongoing Phase 3 PHOENIX clinical trial evaluating AMX0035.
- Commitment to bringing new and effective treatments to the ALS community.
- Positive safety and efficacy data supporting AMX0035.
- Expanded Access Program providing access to AMX0035 for eligible patients.
Headwinds
- Uncertainty regarding the timing of FDA review and potential approval of AMX0035.
- Dependence on the success of AMX0035.
- Risks associated with clinical trials and regulatory processes.
- Potential impact of the COVID-19 pandemic on operations.
- Competition from other companies developing treatments for ALS.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2022
+0.3%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+7.4%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+23.4%
Q4 2021
Best reaction
-30.7%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -7.6% | -9.5% | -2.3% | |
| Q3 2025 | -5.9% | -4.2% | +7.3% | |
| Q1 2025 | -6.0% | -7.8% | +9.4% | |
| Q4 2024 | +0.3% | +29.0% | +17.0% | |
| Q3 2024 | +7.7% | +0.3% | -17.4% | |
| Q2 2024 | +1.1% | +5.9% | +26.1% | |
| Q1 2024 | -8.8% | -3.1% | -8.3% | |
| Q4 2023 | +15.3% | +24.1% | -82.1% | |
| Q3 2023 | -30.7% | -30.4% | -22.2% | |
| Q2 2023 | +0.5% | -2.3% | -4.5% | |
| Q1 2023 | -4.4% | -6.1% | -11.9% | |
| Q4 2022 | +11.2% | -1.2% | -3.9% | |
| Q3 2022 | -1.8% | +2.4% | +3.0% | |
| Q3 2021 | -1.8% | +2.4% | +3.0% | |
| Q2 2021 | -5.5% | -5.7% | +12.7% | |
| Q2 2022 | -5.5% | -5.7% | +12.7% | |
| Q4 2021 | +23.4% | +28.2% | +97.5% | |
| Q1 2022 | +23.4% | +28.2% | +97.5% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro